Alzamend Neuro, Inc. (ALZN) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
3500 LENOX RD. NE ATLANTA, GA 30326 |
| State of Incorp. | DE |
| Fiscal Year End | April 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 1/31/2023 MRQ | 4/30/2022 | 4/30/2021 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 7,376 | 14,064 | 1,929 | ||
| Cash and cash equivalents | 7,376 | 14,064 | 1,929 | ||
| Prepaid expense | 495 | 163 | 1 | ||
| Deferred costs | 353 | ||||
| Other undisclosed current assets | 546 | 187 | 630 | ||
| Total current assets: | 8,417 | 14,414 | 2,913 | ||
| Noncurrent Assets | |||||
| Property, plant and equipment | 85 | 103 | |||
| Total noncurrent assets: | 85 | 103 | |||
| TOTAL ASSETS: | 8,502 | 14,516 | 2,913 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,642 | 1,163 | 504 | ||
| Accounts payable | 2,642 | 1,163 | 504 | ||
| Due to related parties | 2 | 61 | |||
| Other undisclosed current liabilities | 335 | ||||
| Total current liabilities: | 2,642 | 1,165 | 900 | ||
| Noncurrent Liabilities | |||||
| Total liabilities: | 2,642 | 1,165 | 900 | ||
| Equity | |||||
| Equity, attributable to parent, including: | 5,860 | 13,352 | 2,013 | ||
| Preferred stock | 0 | ||||
| Common stock | 10 | 10 | 7 | ||
| Additional paid in capital | 61,500 | 57,420 | 33,722 | ||
| Accumulated deficit | (40,767) | (29,194) | (16,832) | ||
| Other undisclosed equity, attributable to parent | (14,883) | (14,883) | (14,883) | ||
| Total equity: | 5,860 | 13,352 | 2,013 | ||
| TOTAL LIABILITIES AND EQUITY: | 8,502 | 14,516 | 2,913 | ||
Income Statement (P&L) ($ in thousands)
| 1/31/2023 TTM | 4/30/2022 | 4/30/2021 | ||
|---|---|---|---|---|
| Operating expenses | (15,438) | (12,320) | (4,952) | |
| Operating loss: | (15,438) | (12,320) | (4,952) | |
| Nonoperating expense | (4) | (43) | (95) | |
| Interest and debt expense | 43 | 4 | 62 | |
| Loss from continuing operations before equity method investments, income taxes: | (15,399) | (12,358) | (4,984) | |
| Other undisclosed loss from continuing operations before income taxes | (4) | (4) | (62) | |
| Loss from continuing operations: | (15,403) | (12,362) | (5,047) | |
| Loss before gain (loss) on sale of properties: | (9,976) | (12,362) | (5,047) | |
| Other undisclosed net income | 10,828 | |||
| Net loss: | (4,576) | (12,362) | (5,047) | |
| Other undisclosed net loss attributable to parent | (10,866) | |||
| Net loss available to common stockholders, diluted: | (15,442) | (12,362) | (5,047) | |
Comprehensive Income ($ in thousands)
| 1/31/2023 TTM | 4/30/2022 | 4/30/2021 | ||
|---|---|---|---|---|
| Net loss: | (4,576) | (12,362) | (5,047) | |
| Comprehensive loss, net of tax, attributable to parent: | (4,576) | (12,362) | (5,047) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.